INT192806

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.27
First Reported 2006
Last Reported 2010
Negated 1
Speculated 1
Reported most in Body
Documents 11
Total Number 12
Disease Relevance 9.12
Pain Relevance 0.37

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (SSRP1) chromosome (SSRP1) nucleus (SSRP1)
DNA binding (SSRP1) cytoplasm (SSRP1)
Anatomy Link Frequency
neurite 2
sensory neurons 1
neurons 1
SSRP1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Nerve growth factor 59 96.72 Very High Very High Very High
depression 4 73.20 Quite High
peripheral neuropathy 14 69.52 Quite High
Pain 19 60.64 Quite High
Spinal cord 11 24.48 Low Low
Peripheral nerve injury 7 16.24 Low Low
Chemotherapy induced neuropathy 7 8.48 Low Low
cytokine 42 5.00 Very Low Very Low Very Low
imagery 29 5.00 Very Low Very Low Very Low
Central nervous system 21 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cold Sores 367 100.00 Very High Very High Very High
Toxicity 242 100.00 Very High Very High Very High
Congenital Anomalies 7 100.00 Very High Very High Very High
Hypocalcemia 24 99.48 Very High Very High Very High
Pancreatic Cancer 11 98.92 Very High Very High Very High
Disease 40 98.16 Very High Very High Very High
Apoptosis 75 97.48 Very High Very High Very High
Cancer 295 95.12 Very High Very High Very High
Hypomagnesemia 16 94.84 High High
Glioma 11 94.84 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
When our FACT?
FACT Binding (When) of
1) Confidence 0.27 Published 2010 Journal Clinics (Sao Paulo) Section Body Doc Link PMC3020333 Disease Relevance 1.07 Pain Relevance 0.06
The DNA binding of Cisplatin also results in damage to a large number of genes [28], which would have consequences for transcription and consequent general metabolism of the cell.
Cisplatin Binding (binding) of
2) Confidence 0.12 Published 2007 Journal BMC Neurosci Section Body Doc Link PMC1950519 Disease Relevance 0.59 Pain Relevance 0.05
Post-mitotic sensory neurons such as Dorsal root ganglia (DRG) neurons are also particularly susceptible to Cisplatin binding [29] and DNA damage, although this can be rescued by administration of 100 ng/ml NGF [30,31].
Cisplatin Binding (binding) of in sensory neurons associated with nerve growth factor
3) Confidence 0.12 Published 2007 Journal BMC Neurosci Section Body Doc Link PMC1950519 Disease Relevance 0.52 Pain Relevance 0.13
M alone (z P < 0.01 in combination with Cisplatin 1 ?
Cisplatin 1 Binding (combination) of
4) Confidence 0.12 Published 2007 Journal BMC Neurosci Section Body Doc Link PMC1950519 Disease Relevance 0.69 Pain Relevance 0
Although Cisplatin produces its anti-neoplastic effects by binding directly to DNA, resulting in cross-linking and production of apoptosis in rapidly dividing cells [2], as neurons are post-mitotic, the mechanism by which it induces neuropathy is not clear.
Cisplatin Spec (clear) Binding (binding) of in neurons associated with neuropathic pain and apoptosis
5) Confidence 0.12 Published 2007 Journal BMC Neurosci Section Body Doc Link PMC1950519 Disease Relevance 0.49 Pain Relevance 0.09
g/ml; ## P < 0.001 in combination with Cisplatin 20 ?
Cisplatin Binding (combination) of
6) Confidence 0.11 Published 2007 Journal BMC Neurosci Section Body Doc Link PMC1950519 Disease Relevance 0.68 Pain Relevance 0
This neurite toxicity was exacerbated in combination with Cisplatin, with increased toxicity compared to PXD at 10 ?
Cisplatin Binding (combination) of in neurite associated with toxicity
7) Confidence 0.11 Published 2007 Journal BMC Neurosci Section Body Doc Link PMC1950519 Disease Relevance 0.71 Pain Relevance 0
Effect of PXD in blocking Cisplatin neurite toxicity
Cisplatin Binding (toxicity) of in neurite associated with toxicity
8) Confidence 0.11 Published 2007 Journal BMC Neurosci Section Body Doc Link PMC1950519 Disease Relevance 0.57 Pain Relevance 0
However low-dose Cisplatin combined with biological Interferon-alpha therapy has previously not been associated with severe hypocalcaemia in patients with pancreatic cancer.
Cisplatin Binding (associated) of associated with hypocalcemia and pancreatic cancer
9) Confidence 0.05 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1475608 Disease Relevance 1.60 Pain Relevance 0.04
It is generally believed that platinum(IV) compounds need to be reduced in order to bind to the DNA, however, Novakova and others demonstrated that platinum(IV) complexes can bind to DNA directly without previous reduction, even though more slowly and to a lesser extent than cisplatin [21–24, 31–34].
cisplatin Neg (without) Binding (bind) of
10) Confidence 0.02 Published 2009 Journal Metal-Based Drugs Section Body Doc Link PMC2705772 Disease Relevance 0.68 Pain Relevance 0
Only three literature reports have described the association of these electrolyte abnormalities and cisplatin therapy; our case has the longest follow-up.
cisplatin Binding (association) of associated with congenital anomalies
11) Confidence 0.01 Published 2006 Journal BMC Nephrol Section Body Doc Link PMC1481527 Disease Relevance 0.64 Pain Relevance 0
In a comprehensive study of the interaction between NV1066 HSV vector and cisplatin, moderate to strong synergy was observed.
cisplatin Binding (interaction) of associated with cold sores
12) Confidence 0.00 Published 2010 Journal The Open Virology Journal Section Body Doc Link PMC2936037 Disease Relevance 0.88 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox